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Abstract
The External RNA Control Consortium (ERCC) is an ad-hoc group with approximately 70
members from private, public, and academic organizations. The group is developing a set of
external RNA control transcripts that can be used to assess technical performance in gene
expression assays. The ERCC is now initiating the Testing Phase of the project, during which
candidate external RNA controls will be evaluated in both microarray and QRT-PCR gene
expression platforms. This document describes the proposed experiments and informatics process
that will be followed to test and qualify individual controls. The ERCC is distributing this description
of the proposed testing process in an effort to gain consensus and to encourage feedback from the
scientific community. On October 4–5, 2005, the ERCC met to further review the document,
clarify ambiguities, and plan next steps. A summary of this meeting and changes to the test plan are
provided as an appendix to this manuscript.
Background
External RNA controls consortium
The External RNA Control Consortium (ERCC) is an ad-
hoc group with approximately 70 members from private,
public, and academic organizations. The group was initi-
ated in 2003 to develop a set of external RNA control tran-
scripts that can be used to assess technical performance in
gene expression assays. The external RNA controls will be
added after RNA isolation, but prior to cDNA synthesis.
They are being designed to evaluate whether the results for
a given experiment are consistent with defined perform-
ance criteria. All ERCC work is intended to apply to quan-
titative, real-time reverse transcriptase polymerase chain
reaction (QRT-PCR) assays as well as one-color and two-
color microarray experiments.
The ERCC has worked together to define the desired prop-
erties of the transcripts, general protocols for their appli-
cation, and an analysis scheme for performance
assessment. In December 2003, the group developed a
specification document that was discussed and refined in
a public workshop at the National Institute of Standards
and Technology (NIST) [1]. Protocols for the use of exter-
nal RNA controls in clinical applications are included in
the Molecular Methods 16-P document from the Clinical
and Laboratory Standards Institute, and were developed
in a formal, accredited, open, consensus forum including
several ERCC members. The analysis approach was devel-
oped in a public workshop at NIST in June 2004, and is
based upon the measurement of pooled transcripts at
known concentrations.
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erated and collected control sequences, evaluated optimal
polyadenylated (polyA) tail length and identified a path
forward for access and distribution of the controls. We are
now initiating the Testing Phase of the project as
described in this document.
Purpose of this document
During ERCC Testing, candidate external RNA controls
will be evaluated in both microarray and QRT-PCR gene
expression platforms. This document describes the pro-
posed experiments and informatics process that will be
followed to authoritatively test and qualify individual
controls. Qualification of a control sequence is consistent
with the ISO 9000 definition of validation: "Confirma-
tion, through the provision of objective evidence, that
requirements for a specific intended use or application
have been fulfilled." Based on the results of the test and
qualification experiments, the ERCC will select a set of
external RNA controls that perform consistently across
technologies and platforms. DNA clones of the controls,
basic informatics tools and appropriate documentation
will be available to the public. Commercial products (e.g.
primer sets and pools of transcripts) may also be devel-
oped and made available as Certified Reference Materials.
The ERCC is committed to open access and inclusive prac-
tices. We are distributing this description of the proposed
testing process in an effort to gain consensus from the sci-
entific community and to confirm the value of the final
products. We hope it will be carefully reviewed by clinical
and research laboratory scientists. On October 4–5, 2005,
NIST hosted an ERCC Testing Workshop as an open
forum to encourage feedback from the community and to
invite volunteers to participate in the testing phase tasks.
Comments from the meeting are posted on the NIST site
[2] and included in Appendix 2 of this document. Inter-
ested parties should contact Dr. Janet Warrington [3] for
further information.
Specific aims
The five specific aims of the testing project will result in
production of a well-characterized, tested set of controls
with demonstrated acceptable performance on major
microarray platforms and commonly used QRT-PCR
methods. The specific aims are as follows.
1. Design and produce the reagents necessary for the test-
ing plan, including candidate external RNA controls, pro-
totype arrays, primer sets for QRT-PCR and informatics
tools for managing and annotating the testing results.
2. Qualify the reagents. Identify and minimize cross reac-
tivity and potential interactions between the external con-
trols, the probes used for their detection and background
RNA molecules.
3. Qualify the assay by collecting performance data in
multiple gene expression assays. Identify the linear range,
sensitivity and reproducibility of individual candidate
controls. Define performance criteria and select a candi-
date reference set of external RNA controls for future test-
ing.
4. Qualify the product by using the candidate reference set
of external RNA controls in typical microarray and QRT-
PCR assays. Extend analyses to multiple RNA back-
grounds and testing sites. Confirm the performance qual-
ity of the set of transcripts and the informatics tools used
for their analysis. Finalize the reference set and ERCC
products.
5. Distribute DNA clones of the external RNA controls and
informatics tools to general scientific community. Publish
report on ERCC materials, testing data and analysis meth-
ods. Write application use and general protocols.
Definitions, assumptions and limitations
In this document, the term "external RNA controls" refers
to unlabeled, polyadenylated sense transcripts that are
added to an RNA sample prior to processing and used to
measure technical performance of the assay system.
Although labeled transcripts will be generated during the
testing effort to characterize the hybridization dynamics
of each control, the final ERCC product is not intended to
be used as a "hybridization control" in microarray experi-
ments.
Use of external controls
The external RNA controls (sometimes referred to as
"spikes") are intended to be added to total RNA samples
before initiating the gene expression experiment. For
microarray assays, a pool of multiple external RNA con-
trols can be added to a single sample, then labeled and
hybridized in parallel with the target. If each of the added
spikes is introduced at a different concentration, a calibra-
tion curve can be constructed to indicate the linear range
of the hybridization. Different pools of external RNA con-
trols can be used in separate hybridizations (one-color
system) or in different channels of the same hybridization
(two-color system). For QRT-PCR assays, a single external
RNA control can be added to the RNA sample and ampli-
fied simultaneously with the target sequence (two-color
system) or independently in a replicate well (one-color
system).
Current external RNA controls in microarray assays
Several sets of external RNA controls are currently availa-
ble for microarray research [4-9], but few probes corre-Page 2 of 18
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microarrays and there is no consistency across platforms.
As a result of the ERCC effort, a standard set of approxi-
mately 96 well-characterized, external RNA controls will
be available. Many different array manufacturers are par-
ticipating in the ERCC process and have committed to
including probes complementary to the ERCC external
RNA controls on their future microarray products.
Current external RNA controls in QRT-PCR assays
There are two RNA transcript quantification methods for
QRT-PCR assays, absolute and relative quantification.
Absolute quantification is very useful and accurate when
QRT-PCR is used for measuring one or a few targets, but it
often requires generation of template standards for each
target and it may become cumbersome especially when
many targets are analyzed [10,11].
When QRT-PCR is used for gene expression profiling, or
measuring dozens of transcripts simultaneously, relative
quantification is often used. In this case, users rely on
internal genes for normalization, usually a "housekeep-
ing" gene or other transcript whose expression level is
thought to be invariant. This approach has its own limita-
tions. For example, an accurate relative comparison of
gene expression requires similar primer affinities for both
the target and the internal control, which are often diffi-
cult to achieve. Also, recent reports [12-17] have shown
that the expression levels of several housekeeping genes
change in response to drug treatments or environmental
changes, such as stress. These fluctuations raise questions
about the general utility of a single universal set of genes
as internal controls. Finally, the results of QRT-PCR reac-
tions containing QRT-PCR inhibitors in RNA prepara-
tions are cumbersome to correct by using an internal gene
transcript.
External RNA controls would provide an alternative
method for normalization in relative quantification
assays. The combination of external and internal or invar-
iant controls is recommended as the most robust
approach to optimal experimental control. Dose depend-
ence, tissue specificity and degradation issues impact con-
sistency of information and can be controlled for using a
combination of controls. In addition, internal controls are
more appropriately custom designed for analyte control
in assays with a clearly defined intended use and therefore
are by definition assay-dependent. The external RNA con-
trols will provide a complementary resource to internal
and assay-specific custom controls.
Clone collection
The ERCC product will be a set of clones that have been
well characterized for performance on multiple microar-
ray and QRT-PCR platforms. Candidate clones are sub-
mitted to the ERCC and evaluated as described in this
document. Based on the testing results, the ERCC will
select clones that perform acceptably on all participating
platforms to be used as the reference set.
At this time, a number of organizations have submitted
140 candidate transcripts to be tested. As shown in Table
1, the candidate external RNA clones are either synthe-
sized from unique sequences (i.e., artificial) or are derived
from genes in several non-mammalian species. Inserts are
500 – 2000 bp with a 20–30 bp polyadenylated tail. These
clones are given freely without intellectual property rights.
The ERCC welcomes additional submissions. Interested
parties should contact Dr. Janet Warrington for further
information [3].
ERCC products
This work culminates in the selection and distribution of
materials that support the use of external RNA controls in
expression assays. At the completion of the testing phase,
the ERCC will release three products for use by the scien-
tific community:
Table 1: Summary of external RNA control clone library
Number Affiliation of Contributor Genus species Length of RNA
1 – 28 Affymetrix B. subtilis 700–2,000
29 – 40 Affymetrix Artificial Sequences 500–1,900
41 – 43 USDA-ARS-NCAUR Bos taurus 500
44 – 46 USDA-ARS-NCAUR Glycine max 500
47 Ambion Lamda phage 1,000
48 – 53 Ambion Artificial Sequences 750–1,000
54 – 61 Ambion E. coli 750–2,000
62 – 82 Stanford University Methanococcus 500–750
83 – 85 Agilent Technologies Artificial Sequences 500
86 – 90 GE Healthcare E. coli 1,000
91 – 140 Affymetrix/Ambion/Atactic Artificial Sequences 1,000Page 3 of 18
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nal RNA controls
• Basic informatics tools
• Publication of data, test results, protocols
Several additional reagents and documents will be devel-
oped during the testing phase. Many of the documents
will be issued electronically to the general scientific com-
munity via NIST [2] as supplemental information validat-
ing the control production process. Laboratory reagents
will be used exclusively by ERCC members during testing.
Some of the reagents will be donated by participating
ERCC institutions, including array manufacturers, reagent
manufacturers and NIST.
Methods
Testing strategy
The testing work is divided into five sequential phases to
coincide with the specific aims listed above. Milestones
will be used to indicate the completion of each phase
(Table 2).
The proposed methods and specific tasks associated with
each phase of testing are described in the following sec-
tions. The testing will be performed in parallel by three
working groups: microarray group, QRT-PCR group and
informatics group. A fourth group responsible for RNA
production will be contracted by NIST during phase 1. All
of the ERCC members will participate in the documenta-
tion and publication tasks.
Tasks for transcript and other reagent production 
subgroup
This section describes the production and quality control
processes for the candidate external RNA clones used in
testing. NIST will be soliciting these manufacturing tasks
through standard governmental procurement process.
Phase 1 – design and development
• Collect clones
DNA clones for candidate external RNA controls will be
collected and stored in a NIST laboratory. Preliminary
sequence information will also be collected from each
clone contributor. Each clone will be assigned a unique
identification number that coincides with all bioinfor-
matic nomenclature specification requirements. A list of
all candidate external RNA controls with vector, insert
characteristics for the DNA plasmids and E. coli clones
(strains carrying plasmids) will be compiled. This file will
also contain the potential plasmids, which will be used for
the production of the external RNA controls. A portion of
the DNA plasmid or E. coli stock will be sent to the
selected manufacturer(s) for the production of the ERCC
reagents to be used in the testing project.
• Verify DNA sequence
Each plasmid will be grown in a small scale (~10 ml cul-
ture), purified and used for DNA sequence verification.
Primer extension reactions will be designed to obtain full-
length insert sequences. Both strands will be sequenced.
These sequence files will be compared to the sequence
submitted by the clone contributor. It will be important to
verify both the presence of a polyA tail and the 3' restric-
tion site to be used for linearization during in vitro tran-
scription (IVT) template preparation. Ambiguities will be
noted and will be further investigated by re-sequencing
and database comparisons. The ERCC Informatics sub-
group will determine the "correct" sequences to be used
for microarray probe and QRT-PCR primer design. Once
all of the sequences have been collated and verified, these
plasmids will be used for the next phase of production.
• Produce bacterial stocks and plasmids
All of the clones will be grown in 1 liter cultures to gener-
ate 1–2 mg of plasmid DNA. Samples of the bacterial cul-
tures will be saved to create two sets of triplicate glycerol
stocks properly labeled and stored at -80°C. One set will
be sent to NIST and one set will remain at the manufac-
turer's site until the completion of the project, at which
time the second set will be also be returned to NIST. Each
purified plasmid will undergo a set of quality control tests
to measure DNA concentration, confirm purity and verify
the ability to be linearized at a restriction site located 3' of
the polyA tail region. This last confirmation ensures the
usability of the clones in the IVT reactions. The sequence
will be re-verified using a single pass primer extension
Table 2: Summary of testing phases
Testing Phase Specific Aim Milestone
1 – Design & Development Generate Reagents Distribution for prototype testing
2 – Prototype Testing Validate Reagents Initial data collected, acceptance criteria 
established
3 – Proof of Concept Validate Assay Candidate set of ERCC clones
4 – Functional Testing Validate Product Final set of ERCC clones
5 – Performance Review Distribute Product SymposiumPage 4 of 18
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T3).
• Digest plasmids
Each plasmid will be linearized by restriction digestion
using the appropriate amount of DNA needed to produce
the specified amount of transcript. The plasmids will be
inspected by high quality agarose gel electrophoresis to
ensure complete digestion. The linear plasmids will be
purified and concentrations will be normalized to 1 mg/
ml.
• Test IVT template
Approximately 1 ug of each linear plasmid will be used in
a 20 ul IVT reaction. The resulting RNA transcript will be
diluted and inspected on an Agilent 2100 Bioanalyzer.
This analysis will determine whether the size of the RNA
transcript matches the expected length for each plasmid
and whether any of the IVT reactions produced aborted
products. At this stage, the observed transcript RNA yields
will be used to calculate the efficiency of IVT reactions for
each plasmid. Transcription problems will be addressed at
this stage and will help dictate reaction volumes needed
for the large scale IVT reactions in the next phase of pro-
duction.
• Produce RNA transcripts
The IVT reactions will be scaled-up to produce the desired
specified amount of RNA transcript, with considerations
of RNA recovery and reasonable overage. Immediately
after IVT, a small amount of RNA will be analyzed on the
Agilent 2100 Bioanalyzer. If the transcript RNA is the
expected size, it will enter into a large scale RNA purifica-
tion method. The final purified RNA will be normalized
to a concentration of ~1 mg/ml. These will be known as
the "Production RNA Transcript Stocks".
• Verify quality of transcript stocks
The quality of the Production RNA Transcript Stocks will
be assessed for several characteristics, including concen-
tration, purity, integrity, stability and size. Concentration
will be determined using rigorously developed standard
operating procedures for UV absorbance. Purity has two
aspects: the integrity of the transcript (i.e., percentage of
full length transcript) and the stability of the transcript
(i.e., presence of low levels of nucleases). The quality of
the stock transcripts will also be confirmed by measuring
the length of the RNA to determine if it matches the
expected size. The Agilent 2100 Bioanalyzer will be used
for analysis of integrity, stability and nucleotide length.
• Prepare individual stocks of RNA transcripts
The individual RNA transcripts will be diluted in RNA
Storage Buffer (citrate buffer pH 6.3) and normalized to
100 ng/ul at 1000 nt in length. For example, RNA tran-
scripts that are 750, 1200, and 2000 nt in length will be
diluted to 75, 120 and 200 ng/ul respectively.
To determine the molar concentration of 1000 nt tran-
script, a formula or software script will be used to calculate
exact molecular weight (MW) given RNA sequence. The
RNA (single-stranded) molecular weight will be calcu-
Table 3: Description of pools and experiments in microarray testing
Pool External RNA Clones Background RNA No. of Arrays
0 1 to 144 none 0
1 1 to 48 pre-labeled none 3
2 49 to 96 pre-labeled none 3
3 97 to 144 pre-labeled none 3
4 1 to 144pre-labeled none 0
5 1 to 72 (high conc.) 73 to 144 (low conc.) human 3
6 1 to 72 (low conc.) 73 to 144 (high conc.) human 3
7* 1 to 96 (diff. conc.) human 12
8* 1 to 96 human 12
9* 1 to 96 human 12
10* 1 to 96 human 12
11 1 to 96 human 0
12 1 to 96 human 3
13 1 to 96 human 3
14 1 to 96 human 3
Total 75
*Pools 7–10 may be further diluted to expand the concentration range tested.
Array count is per one-color platform and does not include background RNA negative control samples.
Pools 0 and 11 will also be used in QRT-PCR assays.Page 5 of 18
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ecule using the following formula:
MW = (#A × 329.21) + (#C × 305.18) + (#G × 345.21) +
(#U × 306.17) + 18.02
Stocks of individual RNA transcripts will be available in
two forms: 96- well plates or screw-top tubes. Each RNA
will be diluted and 50 ul aliquots of each normalized con-
centration will be transferred to a pre-specified well of a
96-well plate. Wells will be spot-checked for volume.
Plates will be sealed with tape. Barcode tracking will be
utilized to identify lots and all other tracked information.
Plates will be labeled, dated and stored at -80°C until
final packaging and shipping. The RNA transcripts will
also be distributed in individual tubes at an equal molar
concentration (to be determined).
• Prepare pools of RNA transcripts
A series of RNA mixtures will be made according to the
experimental plans. A description of all the pools required
for microarray testing is presented in Table 3. The QRT-
PCR testing generally relies on a series of dilutions of
equal molar pools of the RNA transcripts (pools 0 and 11
in Table 3).
• Manufacture pre-labeled cRNA
The RNA transcripts will be reverse transcribed with an
oligo(dT)-T7 promoter primer and second strand synthe-
sis will be performed to create cDNA templates for the
synthesis of pre-labeled cRNA for each external RNA con-
trol. To allow testing in multiple microarray platforms,
three types of cRNA labels will be used: biotin, DIG and
amino-allyl. This labeled cRNA will be purified and quan-
tified as above, normalized to equal molar concentra-
tions, and pooled as shown in Table 3 to construct
accurate standard signal intensity response curves for each
oligonucleotide probe feature corresponding to the exter-
nal RNA controls.
Tasks for microarray subgroup
This section describes the testing methods necessary to
develop a set of external RNA controls that can be used to
assess the technical performance of microarray experi-
ments. It is anticipated that many of the microarray ven-
dors will participate in the ERCC testing, including
Applied Biosystems, Affymetrix, Agilent, GE Healthcare
and Illumina. Spotted, non-commercial microarrays will
also be contributed by the USDA and NCI. This collection
of microarray products include both one-color platforms,
which hybridize one labeled target to a single microarray,
and two-color platforms, which hybridize two targets with
different labels to a single microarray.
The microarray testing phases are designed to evaluate the
candidate external RNA controls on both one-color and
two-color platforms using the same pools of transcripts.
Many of the experiments are designed to initially generate
sufficient, quality data using relatively few microarrays
and pools of transcripts. They may be expanded to a larger
range of transcript concentrations and/or a greater
number of replicate samples, as desired. A description of
all required external RNA control pools is presented in
Table 3. This plan assumes that phase 1 begins with 144
candidate external RNA controls and that a putative set of
approximately 96 clones has been selected for further
characterization by phase 3.
Phase 1 – design and development
• Design probes and generate commercial microarrays
After sequence verification, each array manufacturer will
design probes targeting all of the candidate external RNA
controls and generate microarrays to be used during test-
ing.
• Design probes and generate non-commercial microarrays
Long DNA oligonucleotide (70-mer) probes will be
designed by a joint effort of USDA and TIGR upon com-
pletion of sequence collection and in silico validation. The
oligonucleotides will be synthesized with 5' amine modi-
fications through a custom synthesis and spotted on glass
slides.
Phase 2 – prototype testing
The goals of the Prototype Testing phase, addressed in two
experiments, are to ensure that the RNA transcript stocks
and the probes to detect each of the external RNA controls
exhibit a basic level of functionality.
• Test probes for cross-hybridization
The first experiment is designed to check for unacceptable
levels of cross-hybridization between the full set of candi-
date probes. To observe hybridization characteristics apart
from labeling efficiencies, cRNA targets for each external
RNA control will be pre-labeled with biotin, DIG or
amino allyl molecules and pooled before hybridization.
Assuming 144 candidate external RNA controls, the pre-
labeled targets will be split into three pools (e.g., controls
1–48 in pool 1, controls 49–96 in pool 2 and controls 97–
144 in pool 3) and a fourth pool of all pre-labeled tran-
scripts will be generated. For one-color platforms, each
pool of targets will be hybridized separately in triplicate
against the test arrays. For two-color platforms, the pool
1–3 transcripts will be coupled to Cy3, while the pool 4
transcripts will be coupled to Cy5. Each test pool of Cy3-
labeled transcripts will be hybridized in triplicate against
reference pool 4 of Cy5-labeled transcripts.Page 6 of 18
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background cRNA. The expected result is that probes will
only show a significant signal when the target they were
designed against is in the pool hybridized to the array (i.e.,
1 of the 3 pools). Examination of the relative signals for
the probes whose targets were hybridized to the arrays
should allow identification of probes that show potential
cross-reactivity to another sequence included in the same
pool. As a negative control, three arrays will be hybridized
to cRNA targets generated from at least one representative
background human sample in the absence of any external
RNA controls. This representative background RNA sam-
ple will be from a human tissue (or set of tissues) chosen
from the Microarray Quality Control Project [18] cur-
rently underway at the FDA-NCTR. As described in the
previous section, RNA from other species can also be
tested for cross hybridization. Probes with minimal cross
hybridization will be incorporated into the set of 96 exter-
nal RNA controls that are further characterized in phase 3.
• Confirm labeling and dose response abilities
The second experiment in the Prototype Testing phase will
test whether the external RNA controls can be labeled in
the presence of a complex background of total RNA. It will
also demonstrate their ability to detect known differences
in transcript abundance between two pools. One pool will
contain external RNA controls in one of two concentra-
tions (e.g., controls 1–72 at 1:10,000 and controls 73–144
at 1:40,000) in the representative human background
total RNA. A second pool will be created in which the con-
centrations are reversed. Both pools will go through three
independent target preparation reactions and hybridiza-
tions. For one-color platforms, each labeled pool of tran-
scripts will be hybridized to a separate microarray. For
two-color platforms, targets from both pools can be
labeled with different Cy dyes and hybridized to the same
microarray. The observed ratios across the two pools will
be compared to the expected 4-fold change. External RNA
controls that do not label or give the expected response
(something reasonably close to a 4:1 intensity ratio) will
be removed from the pool of candidate external RNA con-
trols.
Phase 3 – proof of concept
• Perform modified latin square and graeco-latin square experiments
During the Proof of Concept phase, specific acceptance
metrics will be determined and the performance of each
external RNA control will be tested over a range of concen-
trations. 1:5,000,000 to 1:1,000. The experimental design
for this phase of array testing must meet the following
three criteria: 1) Require a minimal number of arrays and
pools; 2) Introduce transcripts as series of pools with bal-
anced cRNA load that are made at a central site, rather
than in individual testing labs; and 3) Use the same pools
on both one-color and two-color platforms.
To best achieve these objectives, this phase of array testing
is based on modified versions of a Latin Squares design for
Illustrations of latin square and graeco-latin square designsFigu e 1
Illustrations of latin square and graeco-latin square 
designs. "A1" to "A4" number the 4 arrays used in the 
experiment, "G1" to "G4" number the 4 transcripts being 
studied and "L1" to "L4" denote 4 different concentrations 
for each transcript. The four pools of transcripts are labeled 
"W" to "Z". "g" and "r" note the gene concentrations or 
pools used in the green or red channel, respectively of a two-
color experiment.
Table 4: Concentration of controls in dilution 1 pools for modified latin square experiments
Pool Concentration Group A 
(Controls 1–24)
Concentration Group B 
(Clones 25–48)
Concentration Group C 
(Clones 49–72)
Concentration Group D 
(Clones 73–96)
Pool 7 125 1 5 25
Pool 8 25 125 1 5
Pool 9 5 25 125 1
Pool 10 1 5 25 125
Concentration is given as mass ratios, so that "125" represents 1:125,000 or 1 ng of RNA transcript per 125 ng of background RNA where the 
spike amount is adjusted for its length.Page 7 of 18
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two-color platforms [19]. Illustrations of these types of
experiments are given in Figure 1. Panels A and B describe
a 4 × 4 experiment where four different transcripts are
tested at four different concentrations. Panels C, D and E
show how the same 4 × 4 experiment can be accom-
plished on two different platforms using the same four
pools of transcripts.
Phase 3 will characterize a putative set of clones that are
selected based on their performance in phase 2. In this
discussion, we will assume the set includes 96 clones.
These external RNA controls will be split into four groups
of 24 controls each (groups A through D in Table 4). Four
pools of external RNA controls will be created such that
for each pool, each of the four groups of controls will be
at a different concentration (i.e., a different relative mass).
For simplicity, multiple transcripts are present at the same
concentration in this modified design, rather than each
transcript at a different concentration. This design can be
referred to as a modified (or semi-) latin square experi-
ment.
The four pools will be spiked into four independent target
preparation reactions in the presence of the complex back-
ground human total RNA. A single experiment will consist
of triplicate hybridizations of these four samples (see
Table 5). For one-color platforms, each pool will be
hybridized to a separate microarray. For two-color plat-
forms, one pool labeled with Cy3 and another pool
labeled with Cy5 will be hybridized to the same microar-
ray. As a negative control, three arrays will be hybridized
to cRNA targets generated from the background human
sample without any external RNA controls. During analy-
sis, data from both the one-color and two-color arrays will
be normalized using the distribution of signals from the
external RNA control probes, rather than to signals from
the probes that hybridize to the background RNA. This
normalization approach eliminates the need for dye swap
experiments with two-color arrays.
• Expand the range of concentrations tested
A benefit of this simplified design is that it measures the
performance of a large number of external RNA controls
with only 12 arrays (plus the three negative control
arrays), allowing for wider participation during this phase
of testing, instead of limiting participation to those facili-
ties that are able to run the potentially hundreds of arrays
required for complete Latin Square or Graeco-Latin
Square experiments. The potential drawback to this design
is that it allows for measurement of only a limited number
of target concentrations. For those interested in measuring
the external RNA control performance across a wider
range of target concentrations, the experiment can be
expanded without the requirement of additional pools.
This expansion can be accomplished by diluting each of
the pools further to establish other concentration ranges,
prior to introducing them into the background human
total RNA.
Examples of three such dilution ranges are provided in
Table 6. In this illustration, the four pools described in
Table 3 are diluted 2-fold, 4-fold or 40-fold to generate
Dilution 2, Dilution 3 and Dilution 4 pools, respectively.
Sixteen possible pools for testing are generated, which are
labeled based on their pool and dilution numbers: P7-D1;
P7-D2; P7-D3; P7-D4; P8-D1; P8-D2; P8-D3; P8-D4; P9-
D1; P9-D2; P9-D3; P9-D4; P10-D1; P10-D2; P10-D3; and
P10-D4.
Participants can choose to test a few or many different
ranges. Testing all four ranges (i.e., the original stock plus
Dilutions 2–4) would consume 48 arrays (plus the three
negative control arrays) and would measure each of the 96
potential external RNA controls at 16 concentrations
ranging from an estimated mass ratio of 1:1,000 down to
1:5,000,000.
For one-color arrays, each pool would be hybridized to a
separate array, so that 48 microarrays would be required
to generate triplicate sets of data. For two-color platforms,
one pool labeled with Cy3 and another pool labeled with
Cy5 will be hybridized to the same microarray. From
these experiments we will determine the concentration
range over which each target responds linearly. Addition-
ally, we will determine the limit of detection, linear range,
and resolvable fold-change across the linear range for each
external RNA control. As shown in Table 7, the simultane-
ous hybridizations on two-color platforms enable differ-
ential expression evaluations of red/green ratios from 1/
125 (0.008) to 125.
Table 5: Modified latin square hybridization setup
Controls Group Pool 7 Pool 8 Pool 9 Pool 10
A Conc. 1 Conc. 2 Conc. 3 Conc. 4
B Conc. 4 Conc. 1 Conc. 2 Conc. 3
C Conc. 3 Conc. 4 Conc. 1 Conc. 2
D Conc. 2 Conc. 3 Conc. 4 Conc. 1Page 8 of 18
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• Test dose response curve pools
A typical dose response curve (DRC) experiment consists
of testing each external RNA control at multiple concen-
trations, one per array, requiring several arrays. In con-
trast, a single array DRC experiment consists of multiple
concentrations and multiple external RNA controls per
concentration, all tested on a single array. Because the
entire experiment is contained within a single array, each
external RNA control is measured only at a single concen-
tration. Therefore, the intensities from all of the probes
are used together to construct the DRC across the entire
concentration range. During the Functional Testing phase,
the target metrics determined during the Proof of Concept
phase will be used to create a single-array DRC external
RNA control pool. An example single array DRC pool is
shown in Table 8.
To keep the ratio of external RNA controls to background
RNA as low as possible, the higher concentrations of exter-
nal RNA controls (e.g., 1:1,000) are under-represented
compared with the lower concentrations (e.g.,
1:100,000). Additionally, external RNA controls originat-
ing from the same species will be evenly distributed across
the concentration range to minimize the effects of remov-
ing them from experiments performed with background
RNA from the same species.
Up to three pooling schemes will be tested, each with trip-
licate hybridizations. For one-color platforms, each
labeled DRC pool of transcripts will be hybridized to a
separate microarray. For two-color platforms, targets from
different DRC pools can be labeled with different Cy dyes
and hybridized to the same microarray (e.g., pool 12 and
13 or pool 13 and 14).
Table 6: Concentration of controls in dilution pools for expanded range experiments
Pool Conc. A 
Dil. 2
Conc. B 
Dil. 2
Conc. C 
Dil. 2
Conc. D 
Dil. 2
Conc. A 
Dil. 3
Conc. B 
Dil. 3
Conc. C 
Dil. 3
Conc. D 
Dil. 3
Conc. A 
Dil. 4
Conc. B 
Dil. 4
Conc. C 
Dil. 4
Conc. D 
Dil. 4
Pool 7 250 2 10 50 500 4 20 100 5,000 40 200 1,000
Pool 8 50 250 2 10 100 500 4 20 1,000 5,000 40 200
Pool 9 10 50 250 2 20 100 500 4 200 1,000 5,000 40
Pool 10 2 10 50 250 4 20 100 500 40 200 1,000 5,000
Concentration is given as mass ratios, so that "250" represents 1:250,000 or 1 ng of RNA transcript per 250 ng of background RNA, where the 
spike amount is adjusted for its length.
Concentrations of the initial stock, "Dilution 1" pools are shown in Table 4.
Table 7: Expected red:green ratios in two-color hybridizations
Array Pool in Green 
Channel
Pool in Red 
Channel
Group A Ratio Group B Ratio Group C Ratio Group D Ratio
1 P7-D1 P10-D1 0.008 5 5 5
2 P8-D1 P9-D1 0.2 0.2 125 0.2
3 P9-D1 P8-D1 5 5 0.008 5
4 P10-D1 P7-D1 125 0.2 0.2 0.2
5 P7-D2 P8-D2 0.2 125 0.2 0.2
6 P8-D2 P7-D2 5 0.008 5 5
7 P9-D2 P10-D2 0.2 0.2 0.2 125
8 P10-D2 P9-D2 5 5 5 0.008
9 P7-D3 P9-D3 0.04 25 25 0.04
10 P8-D3 P10-D3 0.04 0.04 25 25
11 P9-D3 P7-D3 25 0.04 0.04 25
12 P10-D3 P8-D3 25 25 0.04 0.04
13* P7-D4 P7-D4 1 1 1 1
14* P8-D4 P8-D4 1 1 1 1
15* P9-D4 P9-D4 1 1 1 1
16* P10-D4 P10-D4 1 1 1 1
*Self-to-self hybridizations
Pools in each channel are labeled based on their pool and dilution numbers in Table 6.
Groups are sets of transcripts at the same concentration as defined in Table 4.Page 9 of 18
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Once the final single array DRC pool has been chosen, a
small series of forced failure experiments will be carried
out to mimic how the system will respond to common
failure modes (e.g., incorrect temperature, incorrect buffer
composition, extreme washing stringency, etc.).
Phase 5 – performance review
• Review and publish the experimental results
Results will be shared within the ERCC for review and
evaluation to determine if additional data or redesign is
indicated.
• Repeat experiments in different labs
Tasks for QRT-PCR subgroup
The QRT-PCR testing phases are designed to use the same
pools of transcripts developed for microarray testing and
to evaluate the candidate external RNA controls on multi-
ple QRT-PCR platforms. There are two commonly used
methods of detecting the QRT-PCR amplicons: DNA-
binding dyes (e.g., SYBR Green I) and target-specific
probes with fluorescent 5' exonuclease activity (e.g., Taq-
Man®). The testing plan will generate data on both plat-
forms, using the same primer sets. The DNA-binding
detection assays will use a single tube, one enzyme (rTth)
and SYBR Green I based protocols. The target-specific
detection assays will use a two-step protocol developed
for the TaqMan® system.
Phase 1 – design and development
• Design QRT-PCR primers and detection probes
All primers for external RNA controls will be designed
using commonly used software. Two sets of QRT-PCR
primers (one at 3' and one at 5' end) will be finalized and
used to determine the entirety and specificity of RNA tran-
scripts. For target-specific detection assays, a fluorescent 5'
exonuclease detection probe will also be designed. The
sequences of all QRT-PCR reagents and their locations on
the RNA transcripts as well as the sizes of amplicons and
their predicted Tm will be provided to the community. All
primers and detection probes will be blasted against Gen-
bank for potential cross-reactivity.
• Define cycling parameters
With the DNA-binding detection assays, the concentra-
tion and ratio of primers must be optimized to prevent
fluorescent signal from "primer dimers" or nonspecific
amplicons. Experiments will be performed to develop
amplification parameters for ABI 7900HT and Stratagene
MX3000 using a single tube, one enzyme (rTth) and SYBR
Green I based QRT-PCR protocol. With the target-specific
detection assays, the primer and detection probe concen-
trations and thermal cycling conditions will be as sug-
gested by the manufacturer. cDNA will be generated using
standard kits and random primers prior to amplification.
• Assist in verifying quality of transcript stocks
QRT-PCR will be used to assess the quality of the RNA
transcripts produced for each of the candidate external
RNA controls. Individual transcripts will be evaluated for
entirety, stability, and DNA contamination. The specifi-
city of each primer set and detection probe will be deter-
mined by amplifying individual transcripts in equal molar
pools of the candidate controls. QRT-PCR can also be
used to verify transcript ratios in pools with variable con-
centrations of the candidate controls.
Table 8: Example single array DRC pool
Concentration No. of Targets
1,000 2
2,000 2
4,000 2
5,000 0
10,000 4
20,000 4
25,000 0
40,000 10
50,000 0
100,000 12
125,000 0
200,000 12
250,000 12
500,000 12
1,000,000 12
5,000,000 12
Total 96
Concentration is given as mass ratios, so that "1,000" represents 1:1,000 or 1 ng of RNA transcript per 1,000 ng of background RNA where the spike amount 
is adjusted for its lengthPage 10 of 18
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• Test primers for cross-reactivity
Each set of QRT-PCR primers as well as any detection
probes will be tested for cross-reactivity with other exter-
nal RNA transcripts by amplifying its perspective RNA
transcript from three different RNA sources. First, individ-
ual transcripts will be amplified from a pool containing
multiple RNA transcripts at equal molar concentration
(pool 0 in Table 1). Second, individual transcripts will be
amplified from the same pools of multiple RNA tran-
scripts at equal molar concentration introduced into a
human total RNA background. The human background
RNA increases the complexity of the reaction and may be
based on a reference RNA sample, for example a pool of
RNA derived from 10 different human tissues. Third, indi-
vidual transcripts will be amplified from the human total
RNA that lacks external RNA controls. All amplicons will
be examined by gel electrophoresis or melting dissocia-
tion curves. The Ct values of amplification for each tran-
script under other RNA background should be very similar
to those with only pure RNA transcripts. If any QRT-PCR
reagent gives unexpected products, the primers and/or the
detection probe will be re-designed and re-tested.
• Optimize efficiency of QRT-PCR
A 10-fold serial dilution from 108 copies to 1 copy will be
made for a pool of all candidate RNA transcripts in an
equal molar concentration. The RNA dilutions will be
used for examining the amplification efficiency of at least
one QRT-PCR primer set, and for some platforms the cor-
responding detection probe, for each RNA transcript. Ide-
ally, with a given dilution of the pool, all QRT-PCR primer
sets will amplify their perspective targets with similar effi-
ciency. Otherwise, the primer sets and detection probes
with a low efficiency should be re-designed and re-tested.
• Determine limit of detection
Since all molecular weights and sequences are known, the
physical copies of each RNA transcript in the pool of all
candidate RNA transcripts can be calculated. One RNA
transcript will be chosen as a standard for concentration
determination and the relative concentrations of other
RNA transcripts will be determined based on this stand-
ard. All possible efforts should be made to determine the
copy number of each transcript by QRT-PCR close to its
physical copy number of the RNA transcript in the pool.
The lowest concentration of each transcript in the pool of
all candidate RNA transcripts, which can be detected by
QRT-PCR amplification, can be considered as the limit of
detection for that transcript.
• Assist in verifying quality of pools
QRT-PCR will be used to assess the ratios of different RNA
transcripts in different pools. Note that due to different
amplification efficiencies in RT and PCR, there may be a
discrepancy between the ratios determined by QRT-PCR
and those measured by physical quantity.
Phase 3 – proof of concept
• Establish acceptance criteria for RNA transcripts
Based on the phase 2 results, a set of up to 96 external
RNA controls will be selected for further testing. Using the
10-fold serial dilutions of a pool of these 96 RNA tran-
scripts (pool 11 in Table 1), limit of quantification, line-
arity, precision and accuracy for each of RNA transcript
will be determined, and the acceptance criteria of assay
performance for each RNA transcript will be established.
Those criteria should be established for the pure RNA
transcripts as well as for the pure RNA transcripts under a
background of other total RNA, such as human RNA ref-
erence.
Phase 4 – functional testing
• Compare QRT-PCR platforms and instruments
The QRT-PCR testing will generate data from both DNA-
binding and target-specific detection assays on multiple
thermal cycling instruments, including ABI 7000, ABI
7900HT and Stratagene MX3000. The results will be use-
ful to evaluate the technical performance between those
different instruments and platforms.
• Compare microarray and QRT-PCR platforms
Assay performance of a set of selected external RNA tran-
scripts or pools with the same or different concentrations
will be evaluated by microarray and QRT-PCR. The results
will be very useful to guide the comparison of experimen-
tal results generated by microarray and QRT-PCR.
• Optimize external RNA concentrations
External RNA controls can be used for monitoring the
amplification processes or for detecting the presence of
possible inhibitors in QRT-PCR amplification. Optimal
concentrations of external RNA transcripts should be
established so that the concentrations of the introduced
external RNA controls are low enough to detect the pres-
ence of possible inhibitors, but not too low that the vari-
ation of the assay would be indistinguishable from the
low assay performance caused by inhibitors. Different
concentrations of a given external RNA transcript will be
spiked in total human RNA. The optimal concentration of
an external RNA transcript would give a Ct about 30–32.
Clinical RNA specimens extracted from different tissues
and purified by different sample preparation methods can
be used for evaluating the optimal concentrations of exter-
nal RNA transcripts.
• Conduct forced failure experiments
To establish the utility of external RNA controls for detect-
ing potential QRT-PCR inhibitors, a few known QRT-PCR
inhibitors, such as ethanol and guanidine thiocyanate,Page 11 of 18
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external RNA controls. An impaired QRT-PCR reaction of
external RNA controls could indicate the presence of pos-
sible QRT-PCR inhibitors in the RNA preparation.
• Evaluate multiplex QRT-PCR assays
Multiplex assays are possible when different reporter dyes
are coupled to different target-specific probes so that
cleavage of the multiple probes can be detected in a single
PCR. These multi-color assays may also be performed.
Phase 5 – performance review
• Review and publish the experimental results
• Repeat experiments in different labs
To establish the reproducibility of the research and diag-
nostic utilities of external RNA controls, the experiments
described in phase 4, multi-site testing will be performed.
Tasks for informatics subgroup
The ERCC is committed to delivering an informatics
approach that can be used to establish the technical per-
formance of an expression measurement through the
analysis of the measured response of external spiked-in
RNA controls. This approach will be implemented and
delivered in an open-source manner, such as R code for a
bioconductor package.
The informatics requirements for ERCC development will
include sequence bioinformatics links to public annota-
tion databases. Sequence informatics will be delivered via
these public resources.
The scope of ERCC informatics activity will not include
examination of the application of external RNA controls
for purposes other than evaluation of the technical per-
Table 9: Illustration of a nomenclature system
Reagent Nomenclature Legend
RNA Transcript ERCC-nnnnn-vv nnnnn = unique 5-digit sequence number
vv = 2 digit version number
PCR primer/probe microarray probe ERCC-nnnnn-vv- pppp-lll-aaa pppp = 4-digit positional location relative to the 0th base at the 5' 
end of the transcript sequence
lll = primer/probe length
aaa = nucleic acid sequence of the initial triplet of the primer/probe 
(complement of the RNA sequence at pppp, pppp+1, pppp+2)
Illustration of chi square fitFigu e 2
Illustration of chi square fit. Panel A. The distances from a straight-line fit (arrows) are calculated. Panel B. The Chi square 
fit of the distances is then determined.Page 12 of 18
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tions as normalization to spike-in controls, or calibration,
or evaluation of selectivity and specificity, while poten-
tially useful, are left to assay development efforts for spe-
cific intended use applications.
Phase 1 – design and development
• Develop sequence bioinformatics
The sequence data will need to be managed in a sustaina-
ble fashion using established tools and approaches. At
this stage, sequence bioinformatics includes both a
nomenclature system and a maintainable archive of
sequences. The nomenclature system requires unique
identifiers as well as consistent annotation for RNA con-
trol sequences and the related PCR reagents and microar-
ray probes across various platforms. A preliminary
nomenclature system is presented in Table 9.
The sequence archive requirements are as follows: 1) data
will be stored in FASTA format; 2) where appropriate,
annotation will include unambiguous cross-references to
gene identifiers in public databases; and 3) maintainabil-
ity and version control.
• Explore analytical approaches
The Analytical Informatics work in this phase is explora-
tory and will establish prototype tools for the potential
analysis approaches. The major tasks for the analytical
informatics work at this phase are: 1) identify appropriate
QRT-PCR analysis approaches; 2) investigate various anal-
ysis approaches for microarray technical performance,
including evaluation of preprocessing strategies (e.g., data
normalization); 3) develop prototype tools that can be
used for the exploration of the analysis approaches; and
4) test prototype tools using existing or synthetic data.
The analysis approaches that will be explored in this
phase will include:
Approach 1 – chi square fit of a linear portion of a calibra-
tion curve from the external RNA controls (Figure 2).
Approach 2 – ratio of observed/known concentration
ratios between nearest-neighbor spikes versus concentra-
tion of low spike in pair (Figure 3).
Approach 3 – linear range
1. To characterize an external RNA transcript response we
can describe signal in response to target concentration by
the following general function.
Here, S – signal from microarray element, a – variable
incorporating parameters such as number of probes per
microarray element, number of fluorescent label mole-
cules per target molecule, power of light etc., φ – a func-
tion describing thermodynamics of hybridization
isotherm and this function has a vector of parameters
( ) which is unique for each probe, c – concentrations of
spike-in target, b-background due to dark detector counts
and sources of light other than labeled targets.
2. Let µs(c) be a function describing relationship between
expected signal and spike concentration. Also, let εS(c) be
a function describing relationship between standard devi-
ation of signal and spike concentration.
3 Define signals S and S* (S < S*) as reliably resolved if
Define concentration levels  and  (  < )
as reliably resolved if expected signals produced by these
concentrations are reliably resolved.
Define concentration fold change –  as
reliably resolved if concentration levels  and  are
reliably resolved.
S a c x b=



 +
→
φ ,
x
→
µ ε µ εS S S S+ ≤ −2 2* *
ct
low ct
high ct
low ct
high
f c
c
c
t
low t
high
t
low
( ) =
ct
low ct
high
Illustration of spike performanceFigu e 3
Illustration of spike performance.Page 13 of 18
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are the ends of the longest interval of target concentra-
tions such that f (ct) ≤ 2 ∀ ct ∈ ( , ).
Thus, the linear range is the largest continuous interval of
target concentrations such that a two fold increase of con-
centration anywhere within this interval gives rise to reli-
ably resolved expected signal levels.
4. Using these assumptions we will explore several models
to determine linear range and minimal reliable resolved
concentration fold change.
Approach 4 – fitting the spike-in probe behavior on an
individual array to a reference model of known, accepta-
ble performance (Figure 4).
For 1-color arrays signal intensity can be described as:
Log2I = target concentration + probe affinity + background
+ E
A reference dataset can be used to estimate probe affinity
and background for each of the probes or probe sets. This
should allow for a more accurate estimation of the target
concentration of the external RNA controls.
For 2-color arrays we can use the following model to ana-
lyze spike-in ratios:
Where m and b are the slope and intercept from a least-
squares fit.
This model has the nice feature of physically reasonable
and appealing interpretations of the slope and intercept.
The intercept is the log of the bulk normalization constant
for the external RNA control (i.e., the model is self-nor-
malizing, independent of the normalization of the back-
ground samples carrying the spike-ins). The slope
measures ratio flattening (i.e., reduction of the absolute
value of the log ratio from its expected value, due to such
effects as cross-hybridization of other targets to the spike-
log10
c
c
t
high
t
low
ct
low ct
high
ct
low ct
high
log
NetRedObserved
NetGreenObserved
m ExpectedLogRatio

 = ( ) + b
Illustration of model data (including modeled noise)Figu e 4
Illustration of model data (including modeled noise). The values of m and b that were input into the model were m = 
0.85 and b = 0.08. The noise model is realistic, in that it includes both constant (scanner) and proportional (chemical) noise.Page 14 of 18
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ures to observe expected ratios that are due to normaliza-
tion and effects that are due to ratio flattening. This is
important, because the two effects are often confused and
misdiagnosed.
Approach 5 – ANOVA modeling.
There are several potential approaches to analyzing the
variance in the experiment:
• The variability between repeated probes on the same
array. This will give an indication of the variability due to
spatial distribution and spot deposition.
• Other ANOVA models are possible depending on the
experimental design and the variables captured in the
experiment.
Approach 6 – additional robust measures for performance
metrics will be explored.
Phase 2 – prototype testing
• Develop and test prototype analytic code
Implementations for the analytical approaches will be
developed in the prototyping phase. These implementa-
tions will be tested against modeled/simulated data, as
well as against existing data, where possible. As data
become available from the QRT-PCR and microarray test-
ing activities, those data will be used to evaluate the pro-
totype analytical implementations. The analyses may be
implemented with a variety of numeric and graphical
tools (e.g., spreadsheets or proprietary statistical tools).
Phase 3 – proof of concept
• Qualify analytic models
At this stage of the project, data will become available
from the array and QRT-PCR testing activities. These data
will be used to test the prototype implementations of the
analysis approaches, and those approaches will be refined
as appropriate. Refinements will be tested and qualified.
At the end of this stage, the approaches will be sufficiently
refined to move forward to implementation for functional
testing.
Phase 4 – functional testing
• Prototype open source code for analytics
This stage of the project will focus on developing imple-
mentations of the analysis approaches in R as a biocon-
ductor package. This package should be validated to work
with array data from the variety of microarray platforms
being tested. Refinement of the graphical display of anal-
ysis results will emphasize platform-to-platform consist-
ency where possible (so similar analytical graphs are
presented for 1- and 2-color, and the variety of platforms).
The QRT-PCR analysis approach may be developed as a
separate bioconductor package, with the emphasis likely
to be on a graphical display of performance measures as a
time series.
• Develop web-based interface for analytics
Development of web-based implementations of the anal-
ysis implementations will be investigated, and common
data formats for input and output will be specified and
implemented.
• Qualify final analytic strategy
Phase 5 – performance review
• Publish bioconductor package
The bioconductor package will be published and released
to the community. A manuscript will accompany publica-
tion of the package, describing the analytical approaches
embodied in the package, and demonstrating perform-
ance with the validation data. All relevant performance
data from the testing and development of the ERCC ana-
lytical informatics will be collated and published at this
time.
• Publish sequence database
The reference sequence database will be published and
made available on the web in both flat-file formats and a
common sequence database format (FASTA).
• Publish relevant performance data
Performance data from the testing will be published. Col-
late performance data (from Test Reports), including
probe performance data, in backgrounds.
Test plan tasks for ERCC
• Identify least burdensome path for collection and dis-
tribution of data
• Organize analysis jamboree
• Plan publication of results and timing for publica-
tion(s)
• Organize controls symposium
Conclusion
The tasks described in this document have been designed
and reviewed by many ERCC members. They represent
our best consensus at this time, but may not be the final
format of testing. A summary of the issues discussed at the
ERCC Testing Workshop on October 4–5, 2005 is pro-
vided in Appendix 2 and copies of the presentations are
posted on the NIST website [2]. Additional comments are
welcome and should be sent to Dr. Janet Warrington [3].Page 15 of 18
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Table10: Members of the external RNA controls cosortium
Anne Bergstrom Lucas Agilent Technologies, Inc.
Anne R. Kopf-Sill NuGEN Technologies, Inc
Bin Chen Centers for Disease Control and Prevention
Bud Bromley ViaLogy Corp.
Carole Foy LGC Ltd
Cecelia S. Hinkel Centers for Medicare Medicaid Services
Cecilie Boysen ViaLogy Corp.
Chunmei Liu Affymetrix Inc.
Daya Ranamukha-arachchi FDA/CDRH/OSEL Division of Biology
Elizabeth Wagar UCLA
Ernest S. Kawasaki NCI/NIH
Federico M. Goodsaid CDER/FDA
Friederike Wilmer QIAGEN GmbH
Gavin Fischer Stratagene
Gretchen L. Kiser GE Healthcare
Helen C. Causton Clinical Sciences Centre/Imperial College Microarray Centre
James C. Fuscoe NCTR/FDA
James D. Brenton University of Cambridge
Janet A. Warrington Affymetrix, Inc.
Jesus Soriano ATCC
John Coller Stanford University
John D. Burrill Applied Biosystems
Kate Rhodes Cyntellect Incorporated
Kathleen F. Kerr University of Washington
Kathryn C. Zoon NIAID/NIH
Kathy Lee Applied Biosystems
Laura H. Reid Expression Analysis, Inc.
Leming Shi NCTR/FDA
Marc Salit NIST
Mary Satterfield NIST
Matthew Marton Rosetta Inpharmatics, LLC
Maureen Cronin Genomic Health, Inc.
Michael P. Conley Enzo Life Sciences, Inc.
Mickey Williams Roche
Mike Fero Stanford University
Mike Wilson Ambion, Inc.
Natalia Novoradovskaya Stratagene
Patrick Gilles Invitrogen
Paul K. Wolber Agilent Technologies, Inc.
Pranvera Ikonomi American Type Culture Collection
Raj Puri FDA/Center for Biologics Evaluation and Research
Richard P. Beyer University of Washington
Richard Shippy GE Healthcare
Robert Setterquist Ambion, Inc.
Rosalie K. Elespuru FDA/CDRH/OSEL Division of Biology
Shawn C. Baker Illumina, Inc.
Stephen A. Chervitz Affymetrix, Inc.
Steven R. Bauer FDA/Center for Biologics Evaluation and Research
Steven Russell University of Cambridge
Tamma Kaysser-Kranich GE Healthcare
Theo K. Bammler University of Washington
Thomas B. Ryder Affymetrix, Inc.
Timothy J. Sendera GE Healthcare
Uwe Scherf CDRH/FDA
Xiaolian Gao Atactic Technologies
Xiaoning Wu Roche Molecular Systems, Inc.
Xu Guo Affymetrix, Inc.
Z. Lewis Liu USDA-ARS-NCAUR
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ERCC, External RNA Control Consortium
QRT-PCR, quantitative, real-time reverse transcriptase
polymerase chain reaction
NIST, National Institute of Standards and Technology
polyA, polyadenylated
IVT, in vitro transcription
MW, molecular weight
DRC, dose response curve
Cy, Cyanine Dye
Ct, Cycle Threshold
Appendix
Appendix 1: Members of the external RNA controls 
consortium (Table 10)
Appendix 2: Summary of ERCC test plan workshop
The ERCC reviewed feedback on the Proposed Testing
Plan at a NIST-hosted workshop on October 4–5, 2005.
The meetings were attended by more than 50 participants,
including ERCC members from Europe (Belgium, Ger-
many, UK) and the US. During the first day of the meet-
ing, summaries of the test plan were presented by
representatives from each of the four subgroups. Sug-
gested improvements and possible testing issues were dis-
cussed as listed below:
Reagent production
Perhaps the ERCC set should include different types of
controls (less than 100 bp or no polyA tail) that would
support new labeling technologies or gene expression
applications. Many members liked this possibility, and
although it is outside the scope of the current ERCC initi-
ative, it may develop into future ERCC activities. A request
was made for early release of the submitted but not con-
firmed sequence of the external RNA controls. Another
ERCC deliverable describing how to validate the quality of
the external RNA controls was suggested.
Microarrays
The external RNA control concentrations used during
phase 2 cross hybridization experiments as well as the
exact definition of cross-reactivity were discussed. It was
noted that identifying the specific transcript responsible
for cross hybridization observed in a pool of 24 candi-
dates may require many subsequent hybridizations with
individual controls. Early definitions of the concentra-
tions in the Latin square and dose response curve experi-
ments are needed, with an emphasis on accommodating
the ranges of both channels in two-color arrays. After a
thorough discussion, it was decided to include pre-labeled
external RNA controls in phase 2 of testing. Many of the
microarray technology developers indicated that the test
arrays might include multiple probes or probe sets in
order to identify the best performing sequences. This for-
mat was acceptable, as long as participants agreed not to
change probe sequence between phases.
QRT-PCR
The proposed test plan uses dilutions of equimolar pools
of 96–140 the candidate RNA controls in the QRT-PCR
assays. At the meeting, it was decided that plates of indi-
vidual RNA transcripts would be more useful during the
initial testing in phases 1–4. It was recognized that only
1–3 external RNA controls at a time would be used in
QRT-PCR assays due to limitations in the number of
fluorophors that can be detected. There was also some dis-
cussion that QRT-PCR assay optimization may require
more than 2 primer sets described in the proposed test
plan. A new application for the controls in the validation
of thermal cyclers and other QRT-PCR instruments was
discussed.
Informatics
The ERCC will need a plan for data storage and distribu-
tion. NCI, NCBI, and FDA representatives volunteered to
provide a data repository for Test Plan data. A working
group will be formed to identify needs of the ERCC and
identify which of these data repositories would be a good
fit. Participants were directed to the CLSI MM16-P docu-
ment for a list of possible performance metrics. Prelimi-
nary review of these metrics could be initiated now using
already available gene expression data on many of the
candidate external RNA controls. There was some discus-
sion on whether the external RNA controls should be opti-
mized and selected to have the best possible results (e.g.
perfect dose response curve, no cross hybridization) or left
imperfect to better reflect typical probes or probe sets on
the microarrays.
After nine hours of review and discussion, consensus was
achieved on the ERCC Test Plan by a show of hands with
no major outstanding issues. On the second day of the
meeting, preliminary resource requirements were identi-
fied and the scope of testing (sample number etc.) was
better defined. Key features of this discussion are summa-
rized below:
1. In an effort to efficiently utilize the RNA reagents, early
stages of testing (Phases 1–4) will be performed only at
developer sites and limited to one site per platform. We
estimate that up to 10 microarray and 4 QRT-PCR com-
mercial developers will participate. If resources permit, 3Page 17 of 18
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USDA) will be included to represent home-made, spotted
microarrays.
2. Phase 5 will be divided into two parts with separate
goals. In Phase 5A, the last experiment of Phase 4 will be
repeated at user sites to confirm that results can be repro-
duced using the same materials and protocols as at the
developer sites. In Phase 5B, a set of the best performing
external RNA controls will be distributed to user sites and
incorporated into typical experiments with their materials
and protocols. The intent is to establish performance of
the external RNA controls in a broad variety of routine
applications and protocols. One possible Phase 5B exper-
iment would be to repeat a previous gene expression
experiment to validate that similar differential expression
results are observed with and without the inclusion of
external RNA controls.
3. A tentative list of criteria for technology developers and
user test sites was developed. It was decided that all sites
should have the following attributes: 1) Demonstrated
experience in gene expression platform; 2) Ability to con-
tribute materials and labor; 3) Commitment to deposit all
testing data in publicly available database; and 4) Agree-
ment to meet ERCC timeline. In addition, developer sites
should have demonstrated capacity to design and create
the necessary reagents as well as a commitment to follow
the test plan and collect data on all candidate clones. User
test sites may be asked to contribute a novel application to
the ERCC goals and to provide sample material for the
complex RNA background. It is not necessary to have con-
tributed sequences to be considered as a test site.
4. While the external RNA controls are likely to be useful
in RNA samples from a variety of species, testing will
emphasize human, mouse and rat RNA. A Stratagene rep-
resentative offered to provide universal reference RNA
samples from these three species to be used as the com-
plex RNA background in Phases 1–4. Test microarrays will
include probes or probe sets for both the candidate exter-
nal RNA controls as well as genes included on their typical
human, mouse and rat arrays (as determined by each
developer). This design will enable global normalization
methods and aid in cross hybridization experiments. The
developers may elect to pre-screen their test arrays using
RNA from a variety of species.
Action items and next steps will be further discussed in the
monthly ERCC conference calls.
Note
3Certain commercial equipment, instruments, or materi-
als are identified in this document. Such identification
does not imply recommendation or endorsement by the
National Institute of Standards and Technology, nor does
it imply that the products identified are necessarily the
best available for the purpose.
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